Form 4: Adverum Biotechnologies Director C. David Nicholson Granted Stock Options

Adverum Biotechnologies, Inc. director C. David Nicholson was granted 10,450 stock options with an exercise price of $2.32, vesting on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.

Summary

• C. David Nicholson, a Director of Adverum Biotechnologies, Inc. (ADVM), was granted 10,450 stock options.
• The transaction occurred on June 17, 2025.
• The exercise price for these options is $2.32 per share.
• The options will vest and become exercisable on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.
• Vesting is contingent upon Mr. Nicholson's continued service with the Issuer and includes accelerated vesting upon a change of control.
• The options have an expiration date of June 16, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a neutral to slightly positive event, as it aligns interests and is a standard compensation practice. It doesn't indicate significant positive or negative operational or financial news.

Positives

• The grant of stock options to Director C. David Nicholson aligns his interests with those of shareholders, incentivizing long-term performance and value creation for Adverum Biotechnologies.
• The vesting schedule, tied to continued service, promotes stability in board leadership.

Negatives

• The issuance of stock options can lead to potential dilution for existing shareholders if the options are exercised in the future.

Risks

• The value of the stock options is dependent on the future stock price of Adverum Biotechnologies, Inc. If the stock price does not exceed the exercise price of $2.32, the options may not hold value.
• The vesting of options is subject to the reporting person's continued service, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The stock options granted to Director C. David Nicholson are set to vest on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders, contingent on his continued service, with an expiration date of June 16, 2035.

Industry Context

In the biotechnology sector, equity compensation, such as stock option grants, is a common practice to attract and retain experienced directors and executives. This aligns their financial interests with the long-term success of the company, which is particularly crucial in a research and development-intensive industry like biotech where long-term value creation is paramount.

Comparison to Industry Standards

• The grant of stock options to a director is a standard component of executive and director compensation packages across various industries, including biotechnology.
• While specific comparable companies or projects are not detailed in this filing, such grants are generally benchmarked against peer groups to ensure competitive compensation and alignment with shareholder interests.
• The vesting schedule and option term are typical for such grants.

Corporate Governance

Related Party Transactions

• The stock option grant to C. David Nicholson, a director of Adverum Biotechnologies, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also improved alignment of director interests with shareholder value creation.
• Employees: No direct impact mentioned, but general compensation practices can influence overall company culture and morale.
• Management: Strengthens alignment between the board and executive management through shared equity incentives.

Next Steps

• Continued service of C. David Nicholson with Adverum Biotechnologies, Inc.
• Vesting of the 10,450 stock options on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.
• Potential exercise of the stock options by C. David Nicholson after vesting and before the expiration date of June 16, 2035.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Stock Option Grant, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, C. David Nicholson, Biotechnology